Oligonucleotide Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Antisense Oligonucleotide, Small Interfering RNA, Others), By Application (Neuromuscular Diseases, ATTR, Hepatic VOD, Others), Regional Insights and Forecast to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

OLIGONUCLEOTIDE THERAPEUTICS MARKET OVERVIEW

The global Oligonucleotide Therapeutics Market size estimated at USD 7.93 billion in 2026 and is projected to reach USD 31.2 billion by 2035, growing at a CAGR of 16.43% from 2026 to 2035.

The Oligonucleotide Therapeutics Market has evolved from a specialized genetic-medicine field into an established pharmaceutical segment supported by 24 FDA-approved oligonucleotide drugs through 2025. FDA records identified 10 antisense oligonucleotides, 6 siRNA products, 2 aptamers, 1 defibrotide product, and 1 telomerase inhibitor among approved products as of June 2024, while subsequent approvals expanded the total. Key marketed therapies include nusinersen, patisiran, vutrisiran, inotersen, eplontersen, tofersen, and several exon-skipping medicines. Oligonucleotide therapeutics can selectively influence RNA expression, enabling treatment of genetically defined diseases that previously lacked targeted pharmacological options.

The United States remains the central commercial and regulatory market for oligonucleotide therapeutics, supported by 24 FDA-approved oligonucleotide drugs through 2025 and multiple specialized regulatory pathways for rare diseases. Qalsody received FDA approval on April 25, 2023, while Rivfloza received approval on September 29, 2023, adding further RNA-based options for SOD1-ALS and primary hyperoxaluria type 1. Wainua entered the U.S. market in January 2024, strengthening antisense treatment availability for hereditary transthyretin amyloidosis. The United States also remains important for clinical research, manufacturing investment, patient access programs, and commercialization of antisense and siRNA therapeutics.

KEY FINDINGS

LATEST TRENDS

The latest Oligonucleotide Therapeutics Market trends center on improving delivery, increasing dosing convenience, expanding tissue targeting, and applying antisense and RNA interference mechanisms to diseases beyond traditional rare neurological indications. By 2025, the FDA-approved oligonucleotide landscape had reached 24 drugs, confirming that oligonucleotide therapeutics have progressed from experimental genetic medicines into a broader pharmaceutical modality. The approved portfolio includes 10 ASO products identified by FDA in June 2024 and 6 siRNA products, alongside other oligonucleotide mechanisms.

Ligand-conjugated chemistry is one of the strongest technology trends because conjugating an oligonucleotide with a targeting ligand can improve uptake into specific tissues. Eplontersen, for example, uses ligand-conjugated antisense technology for transthyretin reduction, while siRNA platforms frequently use GalNAc-based targeting to reach hepatocytes. In 2024, Alnylam advanced vutrisiran for ATTR cardiomyopathy following positive HELIOS-B findings and submitted its U.S. supplemental application in October.

MARKET DYNAMICS

Driver

Increasing adoption of RNA-targeted medicines for rare and genetically defined diseases.

The strongest driver of the Oligonucleotide Therapeutics Market is the ability to directly influence disease-related RNA using highly specific sequences. By 2025, the FDA had recognized 24 oligonucleotide therapeutics, demonstrating sustained regulatory acceptance of the modality. Nusinersen established an important precedent for intrathecal antisense treatment of spinal muscular atrophy, while tofersen demonstrated the ability to target a disease-causing genetic mutation in SOD1-ALS. Patisiran also established RNA interference as a clinically validated therapeutic approach after its approval for hereditary transthyretin amyloidosis.

Drivers Impact Analysis*

Restraint

Complex delivery requirements, manufacturing demands, and treatment-associated safety monitoring.

Delivery remains a major restraint because oligonucleotides are larger and more chemically complex than conventional small molecules and can require specialized administration. Intrathecal products such as tofersen require administration into cerebrospinal fluid, creating procedural requirements that can influence treatment access. Chemical modification can improve stability but may introduce additional safety considerations. Sarepta discontinued SRP-5051 in 2024 after prolonged hypomagnesemia and declines in estimated glomerular filtration rate were observed in some participants, demonstrating how adverse-event profiles can interrupt otherwise promising development programs.

Restraints Impact Analysis*

Expansion of ligand-conjugated oligonucleotides into metabolic, cardiovascular, and systemic diseases

Opportunity

The largest opportunity lies in expanding oligonucleotide therapeutics beyond liver-focused applications and established rare neurological disorders. Ligand-conjugated technologies can improve cellular uptake and create opportunities for tissue-selective treatment.

Eplontersen demonstrates the potential of ligand-conjugated antisense technology in transthyretin amyloidosis, while vutrisiran demonstrates the durability potential of subcutaneous RNAi treatment. Alnylam's 2024 supplemental filing for vutrisiran in ATTR cardiomyopathy illustrates how an established oligonucleotide can be expanded into an additional disease manifestation using new clinical evidence.

Achieving efficient delivery to tissues beyond the liver and central nervous system

Challenge

Tissue delivery remains one of the most important scientific challenges because therapeutic activity depends on getting sufficient oligonucleotide concentrations into the correct cells. Liver-directed siRNA has benefited from established ligand-conjugation approaches, whereas skeletal muscle, brain, kidney, lung, and other tissues present additional biological barriers.

The experience of intrathecal therapies demonstrates that direct administration can enable central nervous system exposure, but it can also increase treatment complexity. Similarly, Sarepta's SRP-5051 program showed that improving muscle delivery through peptide-conjugated PMO chemistry must be balanced against systemic safety.

•   
•   
  

  Download Free Sample to learn more about this report

    

OLIGONUCLEOTIDE THERAPEUTICS MARKET SEGMENTATION

By Type

Based on type the market can be categorized into Antisense Oligonucleotide, Small Interfering RNA, Others

• Antisense Oligonucleotide: Antisense oligonucleotides represent the largest type segment in the Oligonucleotide Therapeutics Market. One 2024 market assessment placed ASO-based drugs at 61.2% of the market, reflecting the strong presence of established medicines such as nusinersen, inotersen, eteplirsen, golodirsen, viltolarsen, casimersen, tofersen, and eplontersen. FDA records identified 10 ASO products among approved oligonucleotide products as of June 2024. ASOs can modify RNA through mechanisms such as RNase H-mediated degradation or splice modulation. Exon-skipping therapies have created a specialized commercial segment in Duchenne muscular dystrophy, while tofersen demonstrates ASO application in genetically defined ALS. Ligand-conjugated ASOs are also increasing the potential for systemic delivery.

• Small Interfering RNA: Small interfering RNA represents a major second modality, with FDA records identifying 6 siRNA products as of June 2024. Approved examples include patisiran, givosiran, lumasiran, inclisiran, vutrisiran, and nedosiran. siRNA therapeutics operate through RNA interference, enabling selective degradation of target messenger RNA and reducing production of disease-associated proteins. The modality has achieved particular success in liver-directed diseases because hepatocyte delivery can be facilitated by targeted conjugation technologies. Vutrisiran is an important example, with Alnylam submitting a U.S. supplemental application in October 2024 for ATTR cardiomyopathy based on HELIOS-B findings.

• Others: The Others category includes additional oligonucleotide modalities such as aptamers and specialized nucleotide-based inhibitors. FDA records from June 2024 identified 2 approved aptamer products, including pegaptanib and avacincaptad pegol, alongside defibrotide and imetelstat under separate classifications. Although these products represent smaller portions of the Oligonucleotide Therapeutics Market than ASOs and siRNAs, they demonstrate the breadth of nucleic-acid pharmacology. Aptamers can bind molecular targets through three-dimensional structures, while other oligonucleotide mechanisms can influence telomerase or coagulation-related pathways.

By Application

Based on application the market can be categorized into Neuromuscular Diseases, ATTR, Hepatic VOD, Others

• Neuromuscular Diseases: Neuromuscular diseases represent one of the most established applications for oligonucleotide therapeutics. Based on the 20 FDA CDER-approved oligonucleotide products identified in the June 2024 FDA document, 6 products, or 30%, can be associated directly with neuromuscular indications, including nusinersen, eteplirsen, golodirsen, viltolarsen, casimersen, and tofersen. These therapies demonstrate different mechanisms, including exon skipping and mutant-RNA suppression. Tofersen received U.S. approval in 2023 for adults with SOD1-ALS, adding a genetically targeted neurological application.

• ATTR: ATTR represents a major application for both antisense and siRNA therapeutics. Within the 20 FDA-approved products identified in June 2024, 4 products, representing 20%, directly addressed transthyretin-related disease through inotersen, patisiran, vutrisiran, and eplontersen. These medicines reduce production of transthyretin using different RNA-targeting mechanisms. Vutrisiran became particularly important after positive HELIOS-B findings involving 655 patients, supporting development in ATTR cardiomyopathy. Eplontersen entered the U.S. market in 2024, expanding antisense treatment options for hereditary ATTR polyneuropathy.

• Hepatic VOD: Hepatic veno-occlusive disease represents a specialized application within the Oligonucleotide Therapeutics Market. Defibrotide is the principal approved oligonucleotide-associated therapy for hepatic VOD, accounting for 1 of 20, or 5%, of the FDA-listed oligonucleotide products in the June 2024 classification. Its indication is particularly relevant to patients developing severe hepatic complications following hematopoietic stem-cell transplantation. The application differs from RNA-silencing therapies because defibrotide is a complex polydisperse oligonucleotide mixture rather than a conventional sequence-defined ASO or siRNA.

• Others: Other applications represented 9 of 20, or 45%, of the FDA-listed oligonucleotide products in June 2024 when the products are grouped outside neuromuscular disease, ATTR, and hepatic VOD. This category includes primary hyperoxaluria type 1, hypercholesterolemia, acute hepatic porphyria, geographic atrophy, and other specialized conditions. Rivfloza was approved in September 2023 for primary hyperoxaluria type 1 based on a trial involving 29 patients, while inclisiran extends siRNA technology into cardiovascular risk management. The broad application base demonstrates that the Oligonucleotide Therapeutics Market is expanding beyond rare neurological conditions into metabolic, cardiovascular, ophthalmic, and renal diseases.

•   
•   
  Download Free Sample to learn more about this report

    

OLIGONUCLEOTIDE THERAPEUTICS MARKET REGIONAL INSIGHTS

• North America

North America holds the leading position in the Oligonucleotide Therapeutics Market, with one 2024 assessment assigning the region approximately 58% of global market activity. The United States represents the dominant component because the FDA has approved 24 oligonucleotide drugs through 2025, creating the world's most mature regulatory base for this therapeutic class.

The region hosts major developers including Biogen, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics, supporting clinical research, manufacturing, commercialization, and technology licensing. The United States also demonstrates strong regulatory activity. Qalsody was approved on April 25, 2023, and Rivfloza followed on September 29, 2023.

• Europe

Europe represents the second major regional market for oligonucleotide therapeutics, supported by regulatory harmonization, rare-disease programs, specialist hospitals, and established pharmaceutical manufacturing. One market assessment estimated Europe's 2024 share at approximately 24% of the global oligonucleotide therapeutics market.

The region has also become an important destination for clinical trials because European multicenter studies can recruit patients from multiple national healthcare systems under coordinated regulatory frameworks. Regulatory progress has been particularly visible for neurological applications. In May 2024, the European Commission granted marketing authorization for Qalsody, making tofersen the first therapy authorized specifically for SOD1-ALS in Europe.

• Asia-Pacific

Asia-Pacific is becoming increasingly important in the Oligonucleotide Therapeutics Market because of expanding pharmaceutical research, rising biotechnology investment, genetic-medicine capabilities, and growing healthcare infrastructure. Japan has particular importance because Nippon Shinyaku has established expertise in Duchenne muscular dystrophy therapies, including viltolarsen.

In 2024, Nippon Shinyaku reported continued clinical development and publication activities surrounding viltolarsen, while its research portfolio included multiple rare-disease programs. China is also strengthening its biotechnology capabilities, while Australia participates in multinational clinical research. Japan's regulatory ecosystem provides a significant pathway for rare-disease therapies, and domestic pharmaceutical companies increasingly collaborate with international biotechnology organizations.

• Middle East & Africa

Middle East & Africa represents a smaller portion of the Oligonucleotide Therapeutics Market, but demand is supported by improving genetic-disease diagnosis, specialist healthcare development, and increasing access to advanced medicines. The region's oligonucleotide adoption remains concentrated in major medical centers and countries with stronger pharmaceutical procurement systems.

Rare genetic disorders and inherited metabolic diseases provide important clinical opportunities because oligonucleotide therapeutics can address molecular abnormalities that may have limited conventional treatment options. Healthcare infrastructure remains a defining factor. Oligonucleotide medicines may require genetic confirmation, specialist prescribing, laboratory monitoring, repeated injections, or specialized administration procedures.

KEY INDUSTRY PLAYERS

The global Oligonucleotide Therapeutics Market consists of leading pharmaceutical and biotechnology companies focused on developing antisense oligonucleotide, small interfering RNA, and other RNA-targeted therapies for rare, genetic, neurological, metabolic, and cardiovascular diseases. Companies such as Ionis Pharmaceuticals, Biogen, Alnylam Pharmaceuticals, and Sarepta Therapeutics are strengthening their market presence through advanced antisense and RNA interference platforms, while Jazz Pharmaceuticals and Nippon Shinyaku Co. are expanding their portfolios through specialized therapies targeting rare and genetically driven disorders.

Manufacturers and biotechnology companies including Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, and Nippon Shinyaku Co. are focusing on next-generation oligonucleotide technologies, improved tissue delivery, extended dosing intervals, and precision genetic medicine. The competitive landscape is driven by increasing adoption of RNA-targeted therapies, growing investment in rare-disease treatments, advances in ligand-conjugated delivery technologies, and expanding clinical applications across neurological, neuromuscular, metabolic, cardiovascular, and genetic disorders.

LIST OF TOP OLIGONUCLEOTIDE THERAPEUTICS COMPANIES

• Biogen
• Alnylam Pharmaceuticals
• Sarepta Therapeutics
• Jazz Pharmaceuticals
• Nippon Shinyaku Co.
• Ionis Pharmaceuticals, Inc.

MARKET LEADERSHIP MATRIX: OLIGONUCLEOTIDE THERAPEUTICS MARKET

LEADER INSIGHTS

• ALNYLAM PHARMACEUTICALS: The company maintains a strong position in RNA interference therapeutics, with an established commercial portfolio and continued investment in expanding RNAi-based medicines across multiple disease areas. Its growing pipeline, global commercial capabilities, and focus on advancing RNAi technology support strong future growth potential in the oligonucleotide therapeutics market.

• IONIS PHARMACEUTICALS, INC.: Ionis has extensive expertise in antisense technology and maintains a broad pipeline targeting neurological, cardiovascular, metabolic, and other serious diseases. Its platform capabilities, collaborations, and continued development of antisense medicines strengthen both its current business position and long-term growth prospects.

• BIOGEN: Biogen benefits from substantial global pharmaceutical capabilities, established neurological expertise, and strategic involvement in genetic and RNA-targeted therapeutics. Its research infrastructure, commercial reach, and focus on innovative treatments provide a strong foundation for continued participation in the expanding oligonucleotide therapeutics market.

INVESTMENT ANALYSIS AND OPPORTUNITIES

Investment activity in the Oligonucleotide Therapeutics Market is increasingly focused on delivery technology, chemical modification, rare-disease platforms, and expansion into high-prevalence diseases. The approval of 24 oligonucleotide drugs through 2025 provides a validated commercial and regulatory foundation for continued investment. Investors are particularly interested in companies capable of demonstrating repeatable delivery platforms because improvements in chemistry or targeting can potentially support multiple therapeutic programs. A major investment opportunity lies in ligand-conjugated technology. Eplontersen illustrates how conjugating an antisense molecule with a targeting ligand can support systemic administration for ATTR disease.

Alnylam's vutrisiran program demonstrates another opportunity: an existing RNAi medicine can be investigated for additional disease manifestations, with the HELIOS-B program involving 655 patients and supporting a supplemental U.S. application in 2024. Investment opportunities also exist in CNS and muscle delivery, where biological barriers remain significant. Sarepta's SRP-5051 program demonstrated increased dystrophin expression but was discontinued in 2024 because of safety concerns, showing why investment decisions increasingly require careful assessment of delivery chemistry and long-term tolerability. Companies with validated platforms, strong manufacturing capabilities, and multiple clinical programs can therefore attract strategic partnerships and licensing activity.

NEW PRODUCT DEVELOPMENT

New product development in the Oligonucleotide Therapeutics Market is centered on improved potency, extended dosing intervals, targeted tissue delivery, and expanded disease indications. The FDA-approved landscape reached 24 oligonucleotide drugs by 2025, providing developers with validated mechanisms across ASO, siRNA, aptamer, and other nucleotide-based approaches. The development pipeline is increasingly moving toward chemically modified molecules designed to reduce dosing frequency and improve cellular uptake. Vutrisiran represents an important development model because its established siRNA mechanism was evaluated for ATTR cardiomyopathy after approval for hereditary ATTR polyneuropathy.

In October 2024, Alnylam submitted an sNDA based on HELIOS-B findings, illustrating how lifecycle development can extend the clinical utility of an existing oligonucleotide. In antisense development, Sarepta's SRP-5051 used peptide phosphorodiamidate morpholino oligomer chemistry designed to improve muscle uptake. At a target dose of approximately 30 mg/kg, monthly dosing produced mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks in 20 patients. However, development stopped in November 2024 because of prolonged hypomagnesemia and kidney-function concerns, emphasizing the importance of safety optimization alongside potency.

FIVE RECENT DEVELOPMENTS (2023-2025)

• April 2023: Biogen announced the FDA approval of Qalsody (tofersen), an antisense oligonucleotide therapy for SOD1-ALS. The therapy targets SOD1 messenger RNA to reduce production of the disease-associated protein. The approval strengthened precision-medicine applications within the Oligonucleotide Therapeutics Market and demonstrated the potential of sequence-specific RNA targeting for genetically defined neurological diseases.
• December 2023: Ionis Pharmaceuticals and AstraZeneca announced U.S. approval of Wainua (eplontersen) for hereditary transthyretin-mediated amyloidosis with polyneuropathy. The ligand-conjugated antisense therapy reduces transthyretin production and expanded treatment options for hereditary ATTR. The development strengthened the commercial position of ligand-conjugated antisense technology and demonstrated its potential for systemic administration in genetically driven neurological disorders.
• June 2024: Alnylam Pharmaceuticals announced positive Phase 3 HELIOS-B results for vutrisiran in transthyretin amyloid cardiomyopathy. The study enrolled 654 patients and demonstrated significant reductions in the composite of all-cause mortality and recurrent cardiovascular events. The development strengthened RNA interference technology and supported expansion of vutrisiran into cardiovascular disease, broadening the application landscape for oligonucleotide therapeutics.
• November 2024: Sarepta Therapeutics announced the discontinuation of SRP-5051 development for Duchenne muscular dystrophy. The decision followed safety concerns involving prolonged hypomagnesemia and kidney-function changes during clinical development. The program demonstrated pharmacological activity through increased dystrophin expression, but its discontinuation highlighted the importance of balancing delivery efficiency, molecular potency, and long-term safety in next-generation oligonucleotide therapeutics.
• January 2025: Ionis Pharmaceuticals announced FDA approval of Tryngolza (olezarsen) for adults with familial chylomicronemia syndrome. The antisense oligonucleotide targets apolipoprotein C-III messenger RNA to reduce triglyceride-rich lipoproteins and address a rare genetic lipid disorder. The approval expanded Ionis's commercial oligonucleotide portfolio and demonstrated the broader application of antisense technology in metabolic diseases beyond neurological indications.

OLIGONUCLEOTIDE THERAPEUTICS MARKET REPORT COVERAGE

The Oligonucleotide Therapeutics Market report covers therapeutic modalities, approved products, clinical development, applications, regional performance, competitive positioning, product development, regulatory activity, and strategic investment opportunities. The modality assessment includes antisense oligonucleotides, small interfering RNA, aptamers, and other specialized oligonucleotide technologies. FDA records provide a validated reference point, identifying 20 CDER-approved oligonucleotide products as of June 30, 2024, while subsequent approvals increased the cumulative FDA-approved total to 24 through 2025.

The application analysis covers neuromuscular diseases, ATTR, hepatic VOD, and other metabolic, renal, cardiovascular, ophthalmic, and genetic conditions. The report evaluates key therapies including nusinersen, patisiran, vutrisiran, inotersen, eplontersen, tofersen, and exon-skipping medicines. It also examines administration routes, delivery technologies, molecular mechanisms, and formulation approaches because these factors directly affect clinical adoption and product differentiation. Regional coverage includes North America, Europe, Asia-Pacific, and Middle East & Africa, with particular attention to regulatory activity and clinical infrastructure. Competitive coverage includes Biogen, Alnylam Pharmaceuticals, Sarepta Therapeutics, Jazz Pharmaceuticals, Nippon Shinyaku, and Ionis Pharmaceuticals.